The prospects of Gilead’s top late-stage NASH drug selonsertib grew dim when it kicked off Phase III readouts with a flop. Two months later, the company conceded that a second, much similar trial has also failed.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,